Concurrent chemoradiotherapy for laryngeal preservation in t1/t2 supraglottic squamous cell carcinoma:

Fumihide Rikimaru, Mioko Matsuo, masahiko taura, Yuichiro Higaki, Kichinobu Tomita

Research output: Contribution to journalArticle

Abstract

We treated supraglottic squamous cell carcinoma (T1/2) with chemoradiation for laryngeal preservation and evaluated the effects of the chemoradiation at the dose of 40 Gy as an intermediate evaluation. To investigate the need for this intermediate evaluation, we retrospectively analyzed 46 patients, 43 men and 3 women aged 49 to 86 years, with supraglottic squamous cell carcinoma (T1/2) treated at our institution from January 1997 to May 2008. Overall and cause-specific three-year survival rates were 65% and 77% in all cases, 67% and 75% in T1, and 65% and 77% in T2. The three-year preservation rate of the larynx was 41% in all cases, 51% in T1, and 35% in T2. In the intermediate evaluation, the complete response rate was 58% in all cases, 77% in T1, and 48% in T2. In the cases of larynx preservation, the recurrence rate of the primary site was not significantly different between those cases who did not achieve complete response in the intermediate evaluation and those who did achieve complete response.

Original languageEnglish
Pages (from-to)311-314
Number of pages4
JournalJapanese Journal of Head and Neck Cancer
Volume38
Issue number3
DOIs
Publication statusPublished - Nov 16 2012
Externally publishedYes

Fingerprint

Chemoradiotherapy
Squamous Cell Carcinoma
Larynx
Survival Rate
Recurrence

All Science Journal Classification (ASJC) codes

  • Otorhinolaryngology
  • Oncology

Cite this

Concurrent chemoradiotherapy for laryngeal preservation in t1/t2 supraglottic squamous cell carcinoma: / Rikimaru, Fumihide; Matsuo, Mioko; taura, masahiko; Higaki, Yuichiro; Tomita, Kichinobu.

In: Japanese Journal of Head and Neck Cancer, Vol. 38, No. 3, 16.11.2012, p. 311-314.

Research output: Contribution to journalArticle

@article{82de63800b1b412da791c5ebc31157e2,
title = "Concurrent chemoradiotherapy for laryngeal preservation in t1/t2 supraglottic squamous cell carcinoma:",
abstract = "We treated supraglottic squamous cell carcinoma (T1/2) with chemoradiation for laryngeal preservation and evaluated the effects of the chemoradiation at the dose of 40 Gy as an intermediate evaluation. To investigate the need for this intermediate evaluation, we retrospectively analyzed 46 patients, 43 men and 3 women aged 49 to 86 years, with supraglottic squamous cell carcinoma (T1/2) treated at our institution from January 1997 to May 2008. Overall and cause-specific three-year survival rates were 65{\%} and 77{\%} in all cases, 67{\%} and 75{\%} in T1, and 65{\%} and 77{\%} in T2. The three-year preservation rate of the larynx was 41{\%} in all cases, 51{\%} in T1, and 35{\%} in T2. In the intermediate evaluation, the complete response rate was 58{\%} in all cases, 77{\%} in T1, and 48{\%} in T2. In the cases of larynx preservation, the recurrence rate of the primary site was not significantly different between those cases who did not achieve complete response in the intermediate evaluation and those who did achieve complete response.",
author = "Fumihide Rikimaru and Mioko Matsuo and masahiko taura and Yuichiro Higaki and Kichinobu Tomita",
year = "2012",
month = "11",
day = "16",
doi = "10.5981/jjhnc.38.311",
language = "English",
volume = "38",
pages = "311--314",
journal = "Japanese Journal of Head and Neck Cancer",
issn = "1349-5747",
publisher = "Nihon Tokeibu Gan Gakkai",
number = "3",

}

TY - JOUR

T1 - Concurrent chemoradiotherapy for laryngeal preservation in t1/t2 supraglottic squamous cell carcinoma:

AU - Rikimaru, Fumihide

AU - Matsuo, Mioko

AU - taura, masahiko

AU - Higaki, Yuichiro

AU - Tomita, Kichinobu

PY - 2012/11/16

Y1 - 2012/11/16

N2 - We treated supraglottic squamous cell carcinoma (T1/2) with chemoradiation for laryngeal preservation and evaluated the effects of the chemoradiation at the dose of 40 Gy as an intermediate evaluation. To investigate the need for this intermediate evaluation, we retrospectively analyzed 46 patients, 43 men and 3 women aged 49 to 86 years, with supraglottic squamous cell carcinoma (T1/2) treated at our institution from January 1997 to May 2008. Overall and cause-specific three-year survival rates were 65% and 77% in all cases, 67% and 75% in T1, and 65% and 77% in T2. The three-year preservation rate of the larynx was 41% in all cases, 51% in T1, and 35% in T2. In the intermediate evaluation, the complete response rate was 58% in all cases, 77% in T1, and 48% in T2. In the cases of larynx preservation, the recurrence rate of the primary site was not significantly different between those cases who did not achieve complete response in the intermediate evaluation and those who did achieve complete response.

AB - We treated supraglottic squamous cell carcinoma (T1/2) with chemoradiation for laryngeal preservation and evaluated the effects of the chemoradiation at the dose of 40 Gy as an intermediate evaluation. To investigate the need for this intermediate evaluation, we retrospectively analyzed 46 patients, 43 men and 3 women aged 49 to 86 years, with supraglottic squamous cell carcinoma (T1/2) treated at our institution from January 1997 to May 2008. Overall and cause-specific three-year survival rates were 65% and 77% in all cases, 67% and 75% in T1, and 65% and 77% in T2. The three-year preservation rate of the larynx was 41% in all cases, 51% in T1, and 35% in T2. In the intermediate evaluation, the complete response rate was 58% in all cases, 77% in T1, and 48% in T2. In the cases of larynx preservation, the recurrence rate of the primary site was not significantly different between those cases who did not achieve complete response in the intermediate evaluation and those who did achieve complete response.

UR - http://www.scopus.com/inward/record.url?scp=84868677742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868677742&partnerID=8YFLogxK

U2 - 10.5981/jjhnc.38.311

DO - 10.5981/jjhnc.38.311

M3 - Article

AN - SCOPUS:84868677742

VL - 38

SP - 311

EP - 314

JO - Japanese Journal of Head and Neck Cancer

JF - Japanese Journal of Head and Neck Cancer

SN - 1349-5747

IS - 3

ER -